[go: up one dir, main page]

WO1997035997A3 - Recombinant pox virus encoding myelin protein for therapy - Google Patents

Recombinant pox virus encoding myelin protein for therapy Download PDF

Info

Publication number
WO1997035997A3
WO1997035997A3 PCT/US1997/005217 US9705217W WO9735997A3 WO 1997035997 A3 WO1997035997 A3 WO 1997035997A3 US 9705217 W US9705217 W US 9705217W WO 9735997 A3 WO9735997 A3 WO 9735997A3
Authority
WO
WIPO (PCT)
Prior art keywords
myelin protein
pox virus
therapy
recombinant pox
virus encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/005217
Other languages
French (fr)
Other versions
WO1997035997A9 (en
WO1997035997A2 (en
Inventor
Norman Letvin
Claude P Genain
Linda Gritz
Stephen H Hauser
Dennis Panicali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therion Biologics Corp
Beth Israel Deaconess Medical Center Inc
University of California Berkeley
Original Assignee
Therion Biologics Corp
Beth Israel Deaconess Medical Center Inc
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therion Biologics Corp, Beth Israel Deaconess Medical Center Inc, University of California Berkeley filed Critical Therion Biologics Corp
Priority to AU26586/97A priority Critical patent/AU2658697A/en
Priority to JP9534670A priority patent/JP2000507824A/en
Publication of WO1997035997A2 publication Critical patent/WO1997035997A2/en
Publication of WO1997035997A3 publication Critical patent/WO1997035997A3/en
Publication of WO1997035997A9 publication Critical patent/WO1997035997A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A recombinant pox virus encoding a myelin protein is described. The recombinant pox virus can be used for generating an immune response to the myelin protein. This method involves introducing a sufficient amount of the pox virus to present the myelin protein to the immune system, expressing this myelin protein and presenting the myelin protein to the immune system.
PCT/US1997/005217 1996-03-25 1997-03-25 Recombinant pox virus encoding myelin protein for therapy Ceased WO1997035997A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU26586/97A AU2658697A (en) 1996-03-25 1997-03-25 Recombinant pox virus encoding myelin protein for therapy
JP9534670A JP2000507824A (en) 1996-03-25 1997-03-25 Therapeutic recombinant poxvirus encoding myelin protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1403396P 1996-03-25 1996-03-25
US60/014,033 1996-03-25

Publications (3)

Publication Number Publication Date
WO1997035997A2 WO1997035997A2 (en) 1997-10-02
WO1997035997A3 true WO1997035997A3 (en) 1997-10-30
WO1997035997A9 WO1997035997A9 (en) 1998-01-29

Family

ID=21763138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/005217 Ceased WO1997035997A2 (en) 1996-03-25 1997-03-25 Recombinant pox virus encoding myelin protein for therapy

Country Status (4)

Country Link
JP (1) JP2000507824A (en)
AU (1) AU2658697A (en)
CA (1) CA2250058A1 (en)
WO (1) WO1997035997A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENAIN, C. P. ET AL.: "Inhibition of allergic encephalomyelitis in marmosets by vaccination with recombinant vaccinia virus encoding for Myelin Base Protein", NEUROLOGY, vol. 46, no. 2 suppl., February 1996 (1996-02-01), pages a220 - a221, XP002038649 *
GENAIN, C.P. ET AL.: "Antiboby facilitation of Multiple Sclerosis-like lesions in a nonhuman Primate", JOURNAL OF CLINICAL INVESTIGATION, vol. 96, no. 6, December 1995 (1995-12-01), pages 2966 - 2974, XP002038650 *

Also Published As

Publication number Publication date
JP2000507824A (en) 2000-06-27
AU2658697A (en) 1997-10-17
CA2250058A1 (en) 1997-10-02
WO1997035997A2 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
EP0962467A4 (en) Antibody against human parathormone related peptides
HU9603155D0 (en) Papillomavirus vaccines
EP0219106A3 (en) Polypeptides that elicit antibodies against aids virus
AU2006092A (en) Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
NZ504936A (en) Simultaneous administration of polynucleotide and delayed release polypeptide encoded by the polynucleotide to enhance an immune response of nucleic acid vaccination
EP1063293A3 (en) Transforming growth factor alpha H1
AU1348083A (en) Dna sequences, recombinant dna molecules and preparations of cholera toxin
EP0723555A4 (en) Chimeric proteins which block complement activation
EP0853121A3 (en) Human DNase
EP0361991A3 (en) Method for the microbiological preparation of human serum albumin and other heterologous proteins from a yeast
MY121185A (en) Recombinant antibodies for human therapy.
WO2000000616A3 (en) Marburg virus vaccines
IL91500A0 (en) Protein of paramyxovirus,method for the production thereof and vaccine containing the same
WO1998021343A8 (en) Genes encoding telomerase proteins
AU580059B2 (en) Vaccine against rabies and preparation process thereof
WO1993001210A3 (en) Hcv peptide-antigens and a method of testing for the hepatitis c virus (hcv)
EG18454A (en) Enzymatic membrane method for the synthesis and separation of peptides.
AU7970894A (en) Method of treating depressed reticuloendothelial system function
WO1997035997A3 (en) Recombinant pox virus encoding myelin protein for therapy
EP0609292A4 (en) Soluble variants of type i membrane proteins, and methods of using them.
DE3666666D1 (en) Early-summer meningo-encephalitis virus (fsme-virus) vaccine, and method of producing the same
EP0317279A3 (en) Peptides for use in the purification of factor viii
IE862392L (en) Treatment of high blood pressure
EP0346316A3 (en) Fusion protein and its use
AU5545896A (en) H. Influenzae HxuB and HxuC genes, proteins and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US AM AZ BY KG KZ MD RU TJ TM

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2250058

Country of ref document: CA

Ref country code: CA

Ref document number: 2250058

Kind code of ref document: A

Format of ref document f/p: F